Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis

Author(s):

Ryan Haumschild, PharmD, MS, MBA, CPEL ,Sandy Sallam, PharmD, BCACP, CDCES

Panelists discuss how the safety profiles of second-line primary biliary cholangitis (PBC) therapies in compensated cirrhosis show varying levels of risk, with recent abstracts from EASL and AASLD 2024.

EP: 1.Presentation and Diagnosis of Primary Biliary Cholangitis

EP: 2.Available Treatment Options for PBC

EP: 3.Treatment Goals for Patients With PBC

EP: 4.Exploring Second-Line Treatments for PBC

EP: 5.Examining Elafibranor as a Treatment Option for PBC

EP: 6.Discussing Seladelpar as a Potential Therapeutic for PBC

EP: 7.Long-Term Considerations for PBC Treatment Options

EP: 8.Safety Considerations When Initiating Treatment for PBC

EP: 9.Analyzing Hepatotoxicity as a Safety Concern With PBC Therapies

EP: 10.Additional Safety Considerations With PBC Treatments

Now Viewing

EP: 11.Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis

EP: 12.Long-Term Safety of Second-Line Therapies for PBC

Video content above is prompted by the following:

How do the safety profiles of seladelpar, elafibranor, and obeticholic acid impact their use in patients with compensated cirrhosis?
1. Include in your discussion the EASL 2024 abstract.